YMAB – y-mabs therapeutics, inc. (US:NASDAQ)
Stock Stats
News
9/25
09:42 am
ymab
Neutral
While shareholders of Y-mAbs Therapeutics (NASDAQ:YMAB) are in the black over 1 year, those who bought a week ago aren't so fortunate [Yahoo! Finance]
9/10
09:12 am
ymab
Low
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $23.00 price target on the stock.
9/9
01:03 pm
ymab
Low
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock.
9/6
07:30 am
ymab
Low
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
9/3
08:38 am
ymab
Medium
Y-mAbs to Participate in Upcoming Investor Conferences in September [Yahoo! Finance]
8/12/2024
06:30 am
ymab
-23.5%
MISS
5/7/2024
04:05 pm
ymab
-20.9%
MISS
2/29/2024
04:05 pm
ymab
11.9%
BEAT
11/13/2023
04:05 pm
ymab
9.8%
MISS
9/10
09:12 am
Reiterates
Outperform
Outperform
Wedbush
Low
-2.2%
9/10
09:12 am
Reiterates
Outperform
Outperform
Wedbush
Low
-2.2%
9/10
08:59 am
Reiterates
Outperform
Outperform
Wedbush
Low
2.2%
9/10
08:59 am
Reiterates
Outperform
Outperform
Wedbush
Low
2.2%
9/9
01:03 pm
Reiterates
Overweight
Overweight
Cantor Fitzgerald
Low
-2.4%
9/20
04:16 pm
ymab
Medium
Form 8-K Y-mAbs Therapeutics, For: Sep 17
9/20
04:15 pm
ymab
Medium
Form 4 Y-mAbs Therapeutics, For: Sep 19 Filed by: Gad Thomas
9/17
08:06 pm
ymab
Medium
Form 4 Y-mAbs Therapeutics, For: Sep 13 Filed by: Gad Thomas
9/17
05:24 pm
ymab
Medium
Form 8-K Y-mAbs Therapeutics, For: Sep 11
9/13
04:20 pm
ymab
Medium
Form 144 Y-mAbs Therapeutics, Filed by: Gad Thomas
Show more
Top News Gainers
3/19 Form 4 Y-mAbs Therapeutics, For: Mar 17 Filed by: Moller-San Pedro Claus Juan 22.2%
3/18 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 10.2%
3/13 YmAbs Therapeutics, Inc. (YMAB) Q4 2019 Earnings Call Transcript [The Motley Fool] 9.7%
3/24 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 9.3%
1/15 Form 4 Y-mAbs Therapeutics, For: Jan 13 Filed by: Gad Thomas 9.1%
10/31 Form 8-K Y-mAbs Therapeutics, For: Oct 29 7.9%
4/21 Form 8-K Y-mAbs Therapeutics, For: Apr 15 5.8%
5/14 Form 4 Y-mAbs Therapeutics, For: May 13 Filed by: Gad Thomas 5.7%
6/8 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 5.2%
1/22 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. 5.2%
Top News Decliners
7/1 Form 8-K Y-mAbs Therapeutics, For: Jul 01 -21.3%
3/14 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. -16.7%
10/29 Y-mAbs Announces Proposed Public Offering of Common Stock -10.1%
5/10 Q1/2019 3/31/2019 EPS -0.470 ZacksConsensus N/A ActVsEst N/A - N/A -10.0%
3/5 Y-mAbs to Announce 2019 Financial and Operating Results on March 12, 2020 -8.7%
6/15 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. -6.9%
8/3 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $26.00 price target on the stock. -6.1%
2/27 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.7%
11/1 Form 8-K Y-mAbs Therapeutics, For: Oct 31 -5.6%
10/12 Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. -5.1%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3